Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Exelixis, a development-stage biotechnology company, has submitted an investigational new drug application to the FDA for XL888, a novel anticancer compound.
Subscribe to our email newsletter
XL888 is an orally available small molecule inhibitor of HSP90, which is a chaperone protein that promotes the activity and stability of a range of key regulatory proteins, including kinases. The activity of HSP90 is particularly prominent in tumor cells where it promotes the activity of proteins controlling growth and survival, the company said.
Gisela Schwab, executive vice president and chief medical officer of Exelixis, said: “XL888 inhibits HSP90 with potency comparable to that of natural product-based inhibitors, but with good oral bioavailability and an improved preclinical tolerability profile.
“XL888 exhibits substantial anti-tumor activity at well-tolerated doses in multiple preclinical xenograft models. Therefore, we believe this novel HSP90 inhibitor has the potential to become a best-in-class therapy, and we are excited to advance it into clinical development.”